Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) EBITDA (2018 - 2021)

Historic EBITDA for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q4 2021 value amounting to -$26.4 million.

  • Black Diamond Therapeutics' EBITDA fell 1545.42% to -$26.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$118.9 million, marking a year-over-year decrease of 7652.36%. This contributed to the annual value of -$126.6 million for FY2021, which is 9001.2% down from last year.
  • As of Q4 2021, Black Diamond Therapeutics' EBITDA stood at -$26.4 million, which was down 1545.42% from -$35.1 million recorded in Q3 2021.
  • Over the past 5 years, Black Diamond Therapeutics' EBITDA peaked at -$3.0 million during Q4 2018, and registered a low of -$35.1 million during Q3 2021.
  • Moreover, its 4-year median value for EBITDA was -$13.2 million (2020), whereas its average is -$16.8 million.
  • Within the past 5 years, the most significant YoY rise in Black Diamond Therapeutics' EBITDA was 1035.24% (2020), while the steepest drop was 23530.33% (2020).
  • Over the past 4 years, Black Diamond Therapeutics' EBITDA (Quarter) stood at -$3.0 million in 2018, then tumbled by 224.2% to -$9.9 million in 2019, then tumbled by 131.77% to -$22.9 million in 2020, then fell by 15.45% to -$26.4 million in 2021.
  • Its last three reported values are -$26.4 million in Q4 2021, -$35.1 million for Q3 2021, and -$34.5 million during Q2 2021.